Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 4/20 | 0.62 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564143 | 0.81 | NAMPT (0.51) | CHRM4 | |
| SCHEMBL5567916 | 0.78 | CHRM4 (0.44) | CHRM4HTR2A | |
| SCHEMBL6300800 | 0.78 | LMNA (0.47) | CCR3CHRM4KMT2AMEN1LMNA | |
| SCHEMBL7302889 | 0.78 | LMNA (0.69) | CCR3KMT2AMEN1POLBLMNA | |
| SCHEMBL3946388 | 0.78 | CHRM4 (0.55) | CHRM4 | |
| Oxalic Acid SCHEMBL7318217 | 0.76 | SLC6A2 (0.53) | KMT2AMEN1HTR2A | |
| Oxalic Acid SCHEMBL7320390 | 0.76 | SLC6A4 (0.64) | — | |
| Hydrochloric Acid SCHEMBL7321403 | 0.75 | KCNH2 (0.73) | HTR2A | |
| SCHEMBL6295115 | 0.74 | CHRM4 (0.40) | CCR3CHRM4 | |
| SCHEMBL5563921 | 0.74 | CHRNA7 (0.42) | CCR3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6903103-B2 | Linear cyclic ureas | LES LABORATORIES SERVIER (FR) | 2005-06-07 | — | — | US | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | CCR3 671/4885CCR2 270/4885CHRM4 929/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | CCR3 975/4885CCR2 269/4885CHRM4 1108/4885 |
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | CCR3 975/4885CCR2 269/4885CHRM4 1108/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | CCR3 975/4885CCR2 269/4885CHRM4 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.